ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1774

Sepsis Is The Leading Cause Of Hospital Mortality In Dermatomyositis/Polymyositis: Data From a Population-Based Study

Sara Murray1, Laura Trupin1, Chris Tonner1, Matthew Cascino1, Gabriela Schmajuk1, Mary Margaretten2, Jennifer Barton1, Patricia P. Katz1, Edward H. Yelin3 and Jinoos Yazdany1, 1Medicine, University of California, San Francisco, San Francisco, CA, 2Rheumatology, University of California, San Francisco, San Francisco, CA, 3Medicine, UC San Francisco, San Francisco, CA

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Morbidity and mortality and polymyositis/dermatomyositis (PM/DM)

  • Tweet
  • Email
  • Print
Session Information

Title: Muscle Biology, Myositis and Myopathies I: Insights into Mechanisms of the Idiopathic Inflammatory Myopathies

Session Type: Abstract Submissions (ACR)

Background/Purpose:   Dermatomyositis (DM) and polymyositis (PM) are debilitating inflammatory myopathies with five-year mortality rates estimated to be 33%.  However, the leading causes of inpatient mortality in these conditions have not been fully explored.  In this study, we used a multi-state sample from the Healthcare Cost and Utilization Project (HCUP) to evaluate the sociodemographic and clinical predictors of inpatient mortality in patients with DM/PM.

Methods:   Using the 2009 HCUP State Inpatient Databases for California, New York, Florida, Washington, and Utah, we performed a retrospective study of individuals >18 years of age who met a validated administrative definition of DM/PM.  The primary outcome was death during hospitalization.  Principal diagnoses were determined according to Clinical Classification Software (CCS) codes and variables for interstitial lung disease (ILD), infection, malignancy, and cardiovascular disease (CVD) were generated based on any primary or secondary ICD-9 code falling within these respective diagnostic categories.  A modified Charlson Index was calculated excluding the above diagnoses.  Logistic regression was used to investigate the relationship between inpatient mortality and sociodemographic characteristics (age, gender, race, income), admission characteristics (length of stay, weekend admission), and associated diagnoses (ILD, infection, malignancy, CVD).

Results:   3,300 admissions with PM/DM were identified and inpatient mortality was 3.9% (128 deaths).  Subjects had an average age of 60 years (SD 17), 68% were female, 62% had DM and 38% had PM. In unadjusted analyses, age (65 years in those who died vs. 60 years in those who survived), weekend admission (27% vs. 19%), length of stay (17 vs. 7 days), more comorbidities (Charlson score of 1.4 vs. 1.3), ILD (22% vs. 12%), infection (76% vs. 36%), malignancy (21% vs. 9%), and CVD (51% vs. 29%) were all associated with mortality.  Leading principal diagnoses in subjects who died were septicemia (24%), respiratory failure (17%), pneumonia (9%), aspiration pneumonitis (9%), and acute cerebrovascular disease (5%).   In adjusted logistic regression, age (OR 1.09, 95% CI 1.02-1.17), weekend admission (OR 1.5, 95% CI 1.0-2.3), length of stay (OR 1.05, 95% CI 1.03-1.07), ILD (OR 2.0, 95% CI 1.2-3.1), infection (OR 4.3, 95% CI 2.8-6.5), malignancy (OR 3.2, 95% CI 1.9-5.2), and CVD (OR 2.4, 95% CI 1.6-3.5) were independently associated with mortality (see Table).

Conclusion:   Among hospitalized patients with DM/PM, infection, CVD and factors associated with the disease process (ILD, malignancy) were leading causes of mortality.    Sepsis was the leading cause of death in these patients, suggesting that additional attention to infection prevention in both the inpatient and outpatient settings may significantly improve outcomes.

Table.  Adjusted logistic regression of predictors of inpatient mortality in patients with polymyositis and dermatomyositis in a multi-state population-based sample.

OR (95% CI)

P

Age (per 5 years)

1.09 (1.02-1.17)

<0.05

Female

1.3 (0.8-1.9)

0.2

Race (reference:  white)

 Black

1.3 (0.8-2.1)

0.4

 Hispanic

0.9 (0.5-1.6)

0.7

 Asian/Pacific Islander

1.7 (0.8-3.8)

0.2

 Other

2.0 (0.8-4.9)

0.2

Low Income

0.9 (0.6-1.4)

0.7

Weekend Admission

1.5 (1.0-2.3)

<0.05

Length of Stay (per 2 days)

1.05 (1.03-1.07)

<0.001

Modified Charlson Index

0.89 (0.78-1.01)

0.08

Dermatomyositis (reference polymyositis)

1.0 (0.7-1.5)

0.9

Interstitial Lung Disease

2.0 (1.2-3.1)

<0.01

Infection

4.3 (2.8-6.5)

<0.001

Malignancy

3.2 (1.9-5.2)

<0.001

Cardiovascular disease

2.4 (1.6-3.5)

<0.001


Disclosure:

S. Murray,
None;

L. Trupin,
None;

C. Tonner,
None;

M. Cascino,
None;

G. Schmajuk,
None;

M. Margaretten,
None;

J. Barton,

Pfizer,

2;

P. P. Katz,
None;

E. H. Yelin,
None;

J. Yazdany,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/sepsis-is-the-leading-cause-of-hospital-mortality-in-dermatomyositispolymyositis-data-from-a-population-based-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology